Dengue virus NS2B/NS3 protease inhibitors exploiting the prime side

Journal of Virology

Volumn 91, Issue 10, 2017, Pages

  Lin, Kuan Hung ^a,b   Ali, Akbar ^a   Rusere, Linah ^a   Soumana, Djade I ^a,c   Yilmaz, Nese Kurt ^a   Schiffer, Celia A ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b GENENTECH INC   (United States)

^c GE Healthcare Life Sciences   (United States)

Author keywords

Antimicrobial peptides; Antiviral agents; Dengue fever; Drug design; Protease inhibitors; Receptor ligand interaction; Structural biology; Substrate; Zika

Indexed keywords

APROTININ; ARGININE; CYCLOPEPTIDE; NS2B PROTEASE; NS3 PROTEASE; PROTEINASE INHIBITOR; UNCLASSIFIED DRUG; VIRUS ENZYME; ANTIVIRUS AGENT; NS3 PROTEASE, DENGUE VIRUS; PROTEIN BINDING; SERINE PROTEINASE; VIRAL PROTEIN;

AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ARTICLE; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; DENGUE VIRUS; DRUG DESIGN; DRUG TARGETING; ENZYME ACTIVE SITE; ENZYME INHIBITION; ENZYME INHIBITION ASSAY; ENZYME SUBSTRATE COMPLEX; FLUORESCENCE RESONANCE ENERGY TRANSFER; HYDROGEN BOND; MOLECULAR DYNAMICS; PRIORITY JOURNAL; STRUCTURE ANALYSIS; ANTAGONISTS AND INHIBITORS; CHEMICAL PHENOMENA; CHEMISTRY; COMPUTER SIMULATION; DRUG DEVELOPMENT; DRUG EFFECTS; ENZYMOLOGY; HUMAN; KINETICS; METABOLISM; PROCEDURES; SYNTHESIS;

AMINO ACID SEQUENCE; ANTIVIRAL AGENTS; APROTININ; CATALYTIC DOMAIN; COMPUTER SIMULATION; DENGUE VIRUS; DRUG DISCOVERY; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; KINETICS; PEPTIDES, CYCLIC; PROTEASE INHIBITORS; PROTEIN BINDING; SERINE ENDOPEPTIDASES; VIRAL NONSTRUCTURAL PROTEINS;

EID: 85018333221     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00045-17     Document Type: Article

References (29)

1. Monath TP. 1994. Dengue: the risk to developed and developing countries. Proc Natl Acad Sci U S A 91:2395-2400. https://doi.org/10.1073/ pnas.91.7.2395.
2. WHO. 2009. Dengue: guidelines for diagnosis, treatment, prevention and control. World Health Organization, Geneva, Switzerland.
3. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, Drake JM, Brownstein JS, Hoen AG, Sankoh O, Myers MF, George DB, Jaenisch T, Wint GR, Simmons CP, Scott TW, Farrar JJ, Hay SI. 2013. The global distribution and burden of dengue. Nature 496:504-507. https://doi.org/ 10.1038/nature12060.
4. Rico-Hesse R. 1990. Molecular evolution and distribution of dengue viruses type 1 and 2 in nature. Virology 174:479-493. https://doi.org/ 10.1016/0042-6822(90)90102-W.
5. Chambers TJ, Hahn CS, Galler R, Rice CM. 1990. Flavivirus genome organization, expression, and replication. Annu Rev Microbiol 44: 649-688.
6. Bera AK, Kuhn RJ, Smith JL. 2007. Functional characterization of cis and trans activity of the flavivirus NS2B-NS3 protease. J Biol Chem 282: 12883-12892. https://doi.org/10.1074/jbc.M611318200.
7. Yusof R, Clum S, Wetzel M, Murthy HM, Padmanabhan R. 2000. Purified NS2B/NS3 serine protease of dengue virus type 2 exhibits cofactor NS2B dependence for cleavage of substrates with dibasic amino acids in vitro. J Biol Chem 275:9963-9969. https://doi.org/10.1074/jbc.275.14.9963.
8. Noble CG, Seh CC, Chao AT, Shi PY. 2012. Ligand-bound structures of the dengue virus protease reveal the active conformation. J Virol 86: 438-446. https://doi.org/10.1128/JVI.06225-11.
9. Falgout B, Pethel M, Zhang YM, Lai CJ. 1991. Both nonstructural proteins NS2B and NS3 are required for the proteolytic processing of dengue virus nonstructural proteins. J Virol 65:2467-2475.
10. Yin Z, Patel SJ, Wang WL, Chan WL, Ranga Rao KR, Wang G, Ngew X, Patel V, Beer D, Knox JE, Ma NL, Ehrhardt C, Lim SP, Vasudevan SG, Keller TH. 2006. Peptide inhibitors of dengue virus NS3 protease. Part 2: SAR study of tetrapeptide aldehyde inhibitors. Bioorg Med Chem Lett 16: 40-43.
11. Yin Z, Patel SJ, Wang WL, Wang G, Chan WL, Rao KR, Alam J, Jeyaraj DA, Ngew X, Patel V, Beer D, Lim SP, Vasudevan SG, Keller TH. 2006. Peptide inhibitors of dengue virus NS3 protease. Part 1: warhead. Bioorg Med Chem Lett 16:36-39. https://doi.org/10.1016/j.bmcl.2005.09.062.
12. Nitsche C, Steuer C, Klein CD. 2011. Arylcyanoacrylamides as inhibitors of the dengue and West Nile virus proteases. Bioorg Med Chem 19: 7318-7337. https://doi.org/10.1016/j.bmc.2011.10.061.
13. Nitsche C, Behnam MA, Steuer C, Klein CD. 2012. Retro peptide-hybrids as selective inhibitors of the dengue virus NS2B-NS3 protease. Antiviral Res 94:72-79. https://doi.org/10.1016/j.antiviral.2012.02.008.
14. Bastos Lima A, Behnam MA, El Sherif Y, Nitsche C, Vechi SM, Klein CD. 2015. Dual inhibitors of the dengue and West Nile virus NS2B-NS3 proteases: synthesis, biological evaluation and docking studies of novel peptide-hybrids. Bioorg Med Chem 23:5748-5755. https://doi.org/10 .1016/j.bmc.2015.07.012.
15. Behnam MA, Graf D, Bartenschlager R, Zlotos DP, Klein CD. 2015. Discovery of nanomolar dengue and West Nile virus protease inhibitors containing a 4-benzyloxyphenylglycine residue. J Med Chem 58: 9354-9370. https://doi.org/10.1021/acs.jmedchem.5b01441.
16. Mueller NH, Yon C, Ganesh VK, Padmanabhan R. 2007. Characterization of the West Nile virus protease substrate specificity and inhibitors. Int J Biochem Cell Biol 39:606-614. https://doi.org/10.1016/j.biocel.2006.10 .025.
17. Lin KH, Nalivaika EA, Prachanronarong KL, Yilmaz NK, Schiffer CA. 4 September 2016. Dengue protease substrate recognition: binding of the prime side. ACS Infect Dis https://doi.org/10.1021/acsinfecdis.6b00131.
18. Ang MJ, Lim HA, Poulsen A, Wee JL, Ng FM, Joy J, Hill J, Chia CS. 31 May 2016. Miniature bovine pancreatic trypsin inhibitors (m-BPTIs) of the West Nile virus NS2B-NS3 protease. J Enzyme Inhib Med Chem https:// doi.org/10.1080/14756366.2016.1190713.
19. Chappell KJ, Stoermer MJ, Fairlie DP, Young PR. 2008. West Nile virus NS2B/NS3 protease as an antiviral target. Curr Med Chem 15:2771-2784. https://doi.org/10.2174/092986708786242804.
20. Assenberg R, Mastrangelo E, Walter TS, Verma A, Milani M, Owens RJ, Stuart DI, Grimes JM, Mancini EJ. 2009. Crystal structure of a novel conformational state of the flavivirus NS3 protein: implications for polyprotein processing and viral replication. J Virol 83:12895-12906. https:// doi.org/10.1128/JVI.00942-09.
21. Summa V, Ludmerer SW, McCauley JA, Fandozzi C, Burlein C, Claudio G, Coleman PJ, Dimuzio JM, Ferrara M, Di Filippo M, Gates AT, Graham DJ, Harper S, Hazuda DJ, Huang Q, McHale C, Monteagudo E, Pucci V, Rowley M, Rudd MT, Soriano A, Stahlhut MW, Vacca JP, Olsen DB, Liverton NJ, Carroll SS. 2012. MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants. Antimicrob Agents Chemother 56:4161-4167. https:// doi.org/10.1128/AAC.00324-12.
22. Li J, Lim SP, Beer D, Patel V, Wen D, Tumanut C, Tully DC, Williams JA, Jiricek J, Priestle JP, Harris JL, Vasudevan SG. 2005. Functional profiling of recombinant NS3 proteases from all four serotypes of dengue virus using tetrapeptide and octapeptide substrate libraries. J Biol Chem 280:28766-28774. https://doi.org/10.1074/jbc.M500588200.
23. Leung D, Schroder K, White H, Fang NX, Stoermer MJ, Abbenante G, Martin JL, Young PR, Fairlie DP. 2001. Activity of recombinant dengue 2 virus NS3 protease in the presence of a truncated NS2B co-factor, small peptide substrates, and inhibitors. J Biol Chem 276:45762-45771. https://doi.org/10.1074/jbc.M107360200.
24. Salykin A, Kuzmic P, Kyrylenko O, Musilova J, Glatz Z, Dvorak P, Kyrylenko S. 2013. Nonlinear regression models for determination of nicotinamide adenine dinucleotide content in human embryonic stem cells. Stem Cell Rev 9:786-793. https://doi.org/10.1007/s12015-013-9454-3.
25. özen A, Lin KH, Kurt Yilmaz N, Schiffer CA. 2014. Structural basis and distal effects of Gag substrate coevolution in drug resistance to HIV-1 protease. Proc Natl Acad Sci U S A 111:15993-15998. https://doi.org/10 .1073/pnas.1414063111.
26. Sastry GM, Adzhigirey M, Day T, Annabhimoju R, Sherman W. 2013. Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments. J Comput Aided Mol Des 27:221-234. https://doi.org/10.1007/s10822-013-9644-8.
27. Shivakumar D, Williams J, Wu Y, Damm W, Shelley J, Sherman W. 2010. Prediction of absolute solvation free energies using molecular dynamics free energy perturbation and the OPLS force field. J Chem Theory Comput 6:1509-1519. https://doi.org/10.1021/ct900587b.
28. Humphrey W, Dalke A, Schulten K. 1996. VMD: visual molecular dynamics. J Mol Graph 14:33-38. https://doi.org/10.1016/0263-7855 (96)00018-5.
29. Ozen A, Haliloglu T, Schiffer CA. 2011. Dynamics of preferential substrate recognition in HIV-1 protease: redefining the substrate envelope. J Mol Biol 410:726-744. https://doi.org/10.1016/j.jmb.2011.03.053.